1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Inyx, Inc.

Inyx, Inc.

IYXI
Inyx, Inc.US flagOther OTC
0.00
USD
- -
- -
5,234.00Market Cap
2002 Y
2003 Y
2004 Y
2005 Y
TTM
Revenue per Share
0.01
0.57
0.48
12.46
10.81
Basic EPS, GAAP
-0.02
-0.55
-0.52
-0.78
-0.76
Free Cash Flow per Basic Share
-0.02
-0.6
-0.33
-0.5
-0.58
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-0.04
-0.58
-0.93
-1.54
-1.7
Tangible Book Value per Share
-0.03
- -
-0.23
-1.14
-1.17
Basic Weighted Avg Shares
5
23
33
40
49
Sales/Revenue/Turnover
- -
13
16
496
531
Operating Margin (%)
-176.79
-35.57
-77.96
85.77
78.98
Depreciation Expense
- -
- -
3
7
9
Net Income, GAAP
- -
-12
-17
-31
-37
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-207.57
-95.43
-107.92
-6.26
-6.99
Working Capital
- -
-1
-16
-42
-114
LT Debt
- -
7
- -
46
- -
Total Equity
- -
2
-6
-30
-39
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'06
Jun'06
Sep'06
ST Debt
54
47
108
LT Borrowings
44
42
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
53
53
Market Capitalization
126
117
124

Working Capital

FRC

•

in mil. unless spec.
Mar'06
Jun'06
Sep'06
Total Current Assets
38
38
40
Cash, Cash Equivalents & STI
2
1
2
Accounts Receivable, Net
22
23
23
Inventories
11
10
12
Total Current Liabilities
81
92
153
Payables & Accruals
25
27
26
ST Debt
54
47
108
Deferred Revenue
- -
4
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
418.33%
Free Cash Flow
- -
- -
86.52%
Net Income, GAAP
- -
- -
83.03%
Sales/Revenue/Turnover
- -
- -
3,057.18%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2004
5
3
4
4
16
2005
3
9
13
472
496
2006
21
20
18
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2004
-0.09
-0.11
-0.12
- -
-0.52
2005
-0.18
-0.1
-0.12
- -
-0.78
2006
-0.06
-0.2
-0.19
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2004
- -
- -
- -
- -
- -
2005
- -
- -
- -
- -
- -
2006
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Steven Handley
Full Time Employees
572
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
825 Third Avenue New York City United States of America
IPO Date
Jun 30, 2023
Website
inyxinc.com
Similar Companies
Shop Apotheke Europe N.V. (SAE.DE)
Cawachi Limited (2664.T)
MedAvail Holdings, Inc. (MDVLQ)
Kobo Biotech Ltd. (KOBO.BO)
Patidar Buildcon Limited (PATIDAR.BO)
Orphazyme A/S (0CUM.L)
Business
Inyx, Inc. (IYXI) develops and commercializes innovative pharmaceutical products focused on dermal, nasal, and pulmonary drug delivery systems; its core offerings include branded prescription medications such as Fortical (calcitonin nasal spray) for osteoporosis treatment, as well as generic equivalents and specialty formulations targeting niche therapeutic areas like hormone replacement and respiratory conditions. The company provides contract manufacturing services for nasal sprays and inhalation products, leveraging proprietary pump and aerosol technologies to serve pharmaceutical partners globally. Founded in 1999 and headquartered in Greenville, South Carolina, Inyx operates primarily in the United States with distribution networks extending to Europe and select emerging markets, targeting healthcare providers, wholesalers, and specialty pharmacies in the biopharmaceutical sector. In recent developments within the last two years, Inyx completed a strategic acquisition of a European nasal drug delivery platform in early 2025 to expand its product pipeline; it also secured a $50 million funding round led by healthcare-focused venture investors to support Phase III trials for a novel pulmonary insulin delivery system. Additionally, the company announced a key partnership with a major generic drug manufacturer in late 2024 for co-development of biosimilar inhalation therapies, alongside a corporate reorganization to streamline operations into focused dermal and respiratory segments.